abdominal aortic aneurysm
Conditions
Interventions
intervention group: 4.8mg/kg of sivelestat sodium is dissolved in 50ml of saline and is continuously injected intravenously for 24 hours. The continuous injection is started during the operation and
Sponsors
Keio University, School of Medicine Department of Surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The participants should be over 20 years old and should have written consent to participate in the trial. Patients with the P/F ratio of less than 300mmHg and the chest X-ray showing bilateral infiltration shadow during the operation will be included in the trial, because at the moment, administration of sivelestat sodium is covered by the insurance only for patients with the acute lung injury.
Exclusion criteria
Exclusion criteria: Cases matching following conditions are excluded from the trial. (1)Patients allergic to the components of sivelestat sodium. (2)Patients who are pregnant, have a possibility of pregnancy, and breast-feeding. (3)Patients with evidence of high left atrium pressure. (4)Cases that are considered not eligible for the trial by the doctor in charge. (5)Patients without pulmonary function disorder, meaning patients with the P/F ratio of more than 300 and the chest X-ray that does not show bilateral infiltration shadow during the operation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of postoperative complications, lung injury score, duration of SIRS | — |
Secondary
| Measure | Time frame |
|---|---|
| mortality rate, in-hospital days, period in ICU, mechanical ventilation period, each cytokines | — |
Countries
Japan
Contacts
Public ContactObara Hideaki
Keio University, School of Medicine Department of Surgery
Outcome results
None listed